-Bloomberg
Why Are Zogenix’s Shares Gaining Today?
The FDA has granted Priority Review to Zogenix Inc's (NASDAQ:
Related Posts
That iPhone May Not Cost You $1,000: A ‘Sticky Ecosystem’ Is A Boon For Cell Phone Carriers
Apple Inc. (NASDAQ: AAPL) recently released its latest iPhone 14 models and Bank of America analyst Wamsi Mohan said Wednesday that carrier promotions are making the devices more affordable than shoppers may expect in the inflationary environment.
HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Oren Livnat maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $35 to $30.